- Home
- TBBB vs KYMR Comparison
TBBB vs KYMR Comparison
Compare TBBB & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBBB
- KYMR
- Stock Information
- Founded
- TBBB 2004
- KYMR 2015
- Country
- TBBB Mexico
- KYMR United States
- Employees
- TBBB N/A
- KYMR N/A
- Industry
- TBBB
- KYMR Medicinal Chemicals and Botanical Products
- Sector
- TBBB
- KYMR Health Care
- Exchange
- TBBB NYSE
- KYMR Nasdaq
- Market Cap
- TBBB 2.9B
- KYMR 3.1B
- IPO Year
- TBBB 2024
- KYMR 2020
- Fundamental
- Price
- TBBB $25.51
- KYMR $43.10
- Analyst Decision
- TBBB Hold
- KYMR Strong Buy
- Analyst Count
- TBBB 6
- KYMR 16
- Target Price
- TBBB $32.67
- KYMR $58.94
- AVG Volume (30 Days)
- TBBB 675.3K
- KYMR 569.0K
- Earning Date
- TBBB 08-11-2025
- KYMR 08-06-2025
- Dividend Yield
- TBBB N/A
- KYMR N/A
- EPS Growth
- TBBB N/A
- KYMR N/A
- EPS
- TBBB 0.16
- KYMR N/A
- Revenue
- TBBB $3,027,881,094.00
- KYMR $58,885,000.00
- Revenue This Year
- TBBB $34.03
- KYMR $58.26
- Revenue Next Year
- TBBB $27.47
- KYMR N/A
- P/E Ratio
- TBBB $156.10
- KYMR N/A
- Revenue Growth
- TBBB 31.48
- KYMR N/A
- 52 Week Low
- TBBB $23.00
- KYMR $19.45
- 52 Week High
- TBBB $35.22
- KYMR $53.27
- Technical
- Relative Strength Index (RSI)
- TBBB N/A
- KYMR 46.08
- Support Level
- TBBB N/A
- KYMR $43.21
- Resistance Level
- TBBB N/A
- KYMR $44.94
- Average True Range (ATR)
- TBBB 0.00
- KYMR 1.45
- MACD
- TBBB 0.00
- KYMR -0.42
- Stochastic Oscillator
- TBBB 0.00
- KYMR 13.20
About TBBB BBB FOODS INC
BBB Foods Inc is a company offering a grocery hard discount model in Mexico. Also that operates through three subsidiaries namely Tiendas Tres B, Tiendas BBB and Desarrolladora Tres BSA de CV of which the main activity of Tiendas Tres B is the sale, purchase, distribution and marketing of all types of products, items and goods, as well as the establishment, and operation of individual stores and distribution centers for the sale of such products.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.